Skip to main content

GENELUX Corp

GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001231457

In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $29.5M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $194.3K in total
7
13F holdersQ2 2026, +1 vs. previous quarter
72
13F valueReported value at the end of Q2 2026
$29.5M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding GNLX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding GNLX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by GENELUX Corp insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysCappello JosephChief Technical OfficerSSale−10.3K$2.74−$28.1K−3.1%318.5K after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysZindrick ThomasPresident and CEOSSale−34.5K$2.67−$91.9K−2.7%1.23M after
Sep 2, 2026 (view filing)7:05 PM ETAug 312 daysYu TonyChief Scientific OfficerSSale−9.68K$2.75−$26.7K−3.6%258.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayYu TonyChief Scientific OfficerSSale−653$2.94−$1.92K−0.2%268.4K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayCappello JosephChief Technical OfficerSSale−653$2.95−$1.92K−0.2%328.7K after
Aug 4, 2026 (view filing)8:20 PM ETAug 4Same dayZindrick ThomasPresident and CEOSSale−3.02K$2.95−$8.91K−0.2%1.26M after
Jul 2, 2026 (view filing)4:35 PM ETJul 11 daySmither John WDirectorSSale−12.0K$2.91−$34.9K−11.6%91.4K after
Jun 4, 2026 (view filing)Jun 31 daySmalling RalphHead of RegulatorySSale−192$2.93−$562.56−0.3%67.6K after
Jun 2, 2026 (view filing)Jun 11 dayThomas JohnDirectorSSale−10.0K$2.98−$29.8K−2.1%472.8K after10b5-1
May 12, 2026 (view filing)May 111 dayCappello JosephChief Technical OfficerSSale−605$2.97−$1.80K−0.4%154.5K after

Top 10 13F holders, Q2 2026

The largest institutional positions in GENELUX Corp at the end of Q2 2026; share changes are against Q1 2026.

See all 72 holders
Institutions holding GNLX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Woodward Diversified Capital, LLC2,262,108$6.81M3.00%+144,925+6.8%Added
Vanguard Capital Management LLC1,677,724$5.05M0.00%−17,756−1.0%Reduced
Bleichroeder LP1,380,666$4.16M0.74%00.0%Unchanged
BlackRock, Inc.439,602$1.32M0.00%+33,730+8.3%Added
Geode Capital Management, LLC439,213$1.32M0.00%−14,548−3.2%Reduced
CM Management, LLC400,000$1.20M0.76%+150,000+60.0%Added
Bank of America Corp328,803$989.7K0.00%+4,938+1.5%Added
Vanguard Fiduciary Trust Co236,344$711.4K0.00%−15,266−6.1%Reduced
Flputnam Investment Management Co231,405$696.5K0.01%−49,499−17.6%Reduced
Global Retirement Partners, LLC227,854$685.8K0.01%+227,854New